
Nuvation Bio Expands Safusidenib Trials After Strong Phase 2 Results
Nuvation Bio has reported durable clinical success for its investigational drug safusidenib, with updated Phase 2 data showing a 52% objective response rate in IDH1-mutant glioma patients. Following these results, the company is launching two additional clinical trials to test the inhibitor across a broader range of patient populations.



























